0.4475
price up icon1.64%   0.0072
after-market アフターアワーズ: .45 0.0025 +0.56%
loading
前日終値:
$0.4403
開ける:
$0.442
24時間の取引高:
977.32K
Relative Volume:
0.47
時価総額:
$71.72M
収益:
$46.74M
当期純損益:
$-114.33M
株価収益率:
-0.7443
EPS:
-0.6012
ネットキャッシュフロー:
$-21.04M
1週間 パフォーマンス:
-11.82%
1か月 パフォーマンス:
-20.74%
6か月 パフォーマンス:
-77.17%
1年 パフォーマンス:
-65.58%
1日の値動き範囲:
Value
$0.43
$0.45
1週間の範囲:
Value
$0.43
$0.5399
52週間の値動き範囲:
Value
$0.43
$2.63

Scilex Holding Company Stock (SCLX) Company Profile

Name
名前
Scilex Holding Company
Name
セクター
Healthcare (1176)
Name
電話
(650) 516-4310
Name
住所
960 SAN ANTONIO ROAD, PALO ALTO
Name
職員
113
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
SCLX's Discussions on Twitter

SCLX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
SCLX
Scilex Holding Company
0.4475 71.72M 46.74M -114.33M -21.04M -1.29
Drug Manufacturers - General icon
LLY
Lilly Eli Co
767.76 690.46B 40.86B 8.37B -2.28B 9.25
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
85.00 377.54B 39.36B 13.79B 9.83B 3.086
Drug Manufacturers - General icon
JNJ
Johnson Johnson
144.47 347.83B 87.70B 14.68B 19.03B 6.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
175.58 310.27B 55.53B 5.12B 15.62B 2.88
Drug Manufacturers - General icon
MRK
Merck Co Inc
98.05 248.03B 63.17B 12.15B 14.84B 4.77

Scilex Holding Company Stock (SCLX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-16 開始されました Alliance Global Partners Buy
2024-06-13 開始されました Rodman & Renshaw Buy
2023-10-16 開始されました B. Riley Securities Buy
2023-10-13 開始されました B. Riley Securities Buy
2023-10-09 開始されました H.C. Wainwright Buy

Scilex Holding Company (SCLX) 最新ニュース

pulisher
Dec 19, 2024

Scilex CEO Jaisim Shah buys $13,800 in company stock By Investing.com - Investing.com South Africa

Dec 19, 2024
pulisher
Dec 19, 2024

Scilex CEO Jaisim Shah buys $13,800 in company stock - Investing.com India

Dec 19, 2024
pulisher
Dec 18, 2024

Jaisim Shah Purchases 30,000 Shares of Scilex Holding (NASDAQ:SCLX) Stock - MarketBeat

Dec 18, 2024
pulisher
Dec 16, 2024

Scilex Holding Co options imply 15.0% move in share price post-earnings - TipRanks

Dec 16, 2024
pulisher
Dec 16, 2024

Palo Alto pharmaceutical company secures $17M - Silicon Valley Business Journal

Dec 16, 2024
pulisher
Dec 16, 2024

Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - The Manila Times

Dec 16, 2024
pulisher
Dec 16, 2024

Scilex Holding Company Announces Early Installment Payment - GlobeNewswire

Dec 16, 2024
pulisher
Dec 16, 2024

Scilex Holding Company closes registered direct offering - Medical Buyer

Dec 16, 2024
pulisher
Dec 16, 2024

Holding Company Shares Rally Following Board Of Directors Commentary - MSN

Dec 16, 2024
pulisher
Dec 13, 2024

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - The Eastern Progress Online

Dec 13, 2024
pulisher
Dec 13, 2024

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering - The Manila Times

Dec 13, 2024
pulisher
Dec 12, 2024

Scilex Holding Co options imply 17.2% move in share price post-earnings - TipRanks

Dec 12, 2024
pulisher
Dec 12, 2024

Scilex secures $17 million in stock and warrant sale - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

Scilex Holding Company Announces $17 Million Registered Direct Offering - The Manila Times

Dec 12, 2024
pulisher
Dec 11, 2024

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times

Dec 11, 2024
pulisher
Dec 11, 2024

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - The Manila Times

Dec 11, 2024
pulisher
Dec 11, 2024

Scilex Bio says KDS201 currently enrolling with U.S. patient cohort to be added - TipRanks

Dec 11, 2024
pulisher
Dec 11, 2024

Scilex Bio, a Controlling Interest of Joint Venture by - GlobeNewswire

Dec 11, 2024
pulisher
Dec 11, 2024

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - Yahoo Finance

Dec 11, 2024
pulisher
Dec 11, 2024

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials C - The Manila Times

Dec 11, 2024
pulisher
Dec 10, 2024

SCLX: Deal Brings Huge Potential - Research Tree

Dec 10, 2024
pulisher
Dec 10, 2024

Scilex Holding agrees to share sale to meet debt obligations By Investing.com - Investing.com Nigeria

Dec 10, 2024
pulisher
Dec 10, 2024

Scilex Holding agrees to share sale to meet debt obligations - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

Scilex Announces Joint Venture for CNS Compound Development - TipRanks

Dec 10, 2024
pulisher
Dec 10, 2024

NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes C - The Manila Times

Dec 10, 2024
pulisher
Dec 10, 2024

NeuroBiogen Company and Scilex Bio, a Controlling Interest - GlobeNewswire

Dec 10, 2024
pulisher
Dec 10, 2024

NeuroBiogen Company and Scilex Bio Enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 - Marketscreener.com

Dec 10, 2024
pulisher
Dec 10, 2024

Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and - The Manila Times

Dec 10, 2024
pulisher
Dec 10, 2024

Scilex and IPMC announce joint venture for obesity drug By Investing.com - Investing.com UK

Dec 10, 2024
pulisher
Dec 10, 2024

Scilex Holding Company Enters into a Binding Term Sheet for - GlobeNewswire

Dec 10, 2024
pulisher
Dec 10, 2024

Walmart Inc (WMT-N) QuotePress Release - The Globe and Mail

Dec 10, 2024
pulisher
Nov 28, 2024

Short Interest in Scilex Holding (NASDAQ:SCLX) Decreases By 51.1% - MarketBeat

Nov 28, 2024
pulisher
Nov 23, 2024

Scilex Holding Co reaches agreement to waive default penalties By Investing.com - Investing.com South Africa

Nov 23, 2024
pulisher
Nov 22, 2024

Scilex receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa

Nov 22, 2024
pulisher
Nov 22, 2024

Scilex Holding Co reaches agreement to waive default penalties - Investing.com

Nov 22, 2024
pulisher
Nov 22, 2024

Scilex receives Nasdaq non-compliance notice - Investing.com India

Nov 22, 2024
pulisher
Nov 22, 2024

Scilex Holding Company Announces Receipt of Notice from Nasdaq - The Manila Times

Nov 22, 2024
pulisher
Nov 22, 2024

Scilex Holding Company Announces Receipt of Notice from Nasdaq - GlobeNewswire Inc.

Nov 22, 2024
pulisher
Nov 21, 2024

Sciatica Market Report 2032, DelveInsight | Sciatica Therapies & Companies, Clinical trials, Sciatica Treatment | Scilex Holding Company, Seikagaku Corporation, Sollis Therapeutics, SpineThera, Kol - The Globe and Mail

Nov 21, 2024
pulisher
Nov 18, 2024

Open Text Corp (OTEX-Q) QuotePress Release - The Globe and Mail

Nov 18, 2024
pulisher
Nov 15, 2024

Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 1419, 2024 - The Manila Times

Nov 15, 2024
pulisher
Nov 15, 2024

Scilex Holding Company Announces Presentation of Data at - GlobeNewswire

Nov 15, 2024
pulisher
Nov 15, 2024

Scilex Holding Company Announces Presentation of Data at the 2024 American College of ... - The Bakersfield Californian

Nov 15, 2024
pulisher
Nov 15, 2024

Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024 - Yahoo Finance

Nov 15, 2024
pulisher
Nov 12, 2024

Private companies who have a significant stake must be disappointed along with institutions after Scilex Holding Company's (NASDAQ:SCLX) market cap dropped by US$22m - Simply Wall St

Nov 12, 2024
pulisher
Nov 12, 2024

SCLX stock touches 52-week low at $0.73 amid market challenges - Investing.com

Nov 12, 2024
pulisher
Nov 11, 2024

Denali Capital (DECA) Secures Extension for Merger Deal, Issues $180K Note to Scilex - StockTitan

Nov 11, 2024
pulisher
Nov 07, 2024

Scilex shares face delisting risk on Nasdaq - Investing.com India

Nov 07, 2024
pulisher
Nov 06, 2024

Scilex Holding Plans Merger to Boost Semnur Value - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Pre - The Manila Times

Nov 06, 2024

Scilex Holding Company (SCLX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Scilex Holding Company (SCLX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Ji Henry
Executive Chairperson
Oct 31 '24
Buy
0.94
8,888
8,351
320,161
SHAH JAISIM
See Remarks
Oct 29 '24
Buy
0.99
32,000
31,670
109,333
Followwill Dorman
Director
Oct 18 '24
Buy
0.99
1,000
990
2,300
Chun Jay
Director
Oct 18 '24
Buy
0.95
5,000
4,750
112,500
Wu Yue Alexander
Director
Oct 17 '24
Buy
0.95
20,000
18,992
25,000
Lemus David
Director
Oct 17 '24
Buy
0.90
2,000
1,800
2,000
Ji Henry
Executive Chairperson
Oct 17 '24
Buy
0.97
10,000
9,710
60,070
SHAH JAISIM
See Remarks
Oct 16 '24
Buy
0.99
30,000
29,751
77,333
Ma Stephen Hoi
Chief Financial Officer
Oct 16 '24
Buy
0.97
6,700
6,499
22,840
Followwill Dorman
Director
Jun 26 '24
Option Exercise
1.37
1,000
1,370
1,300
drug_manufacturers_general BMY
$57.33
price up icon 1.83%
drug_manufacturers_general SNY
$47.71
price up icon 0.44%
$263.38
price up icon 0.84%
drug_manufacturers_general PFE
$26.36
price up icon 2.29%
drug_manufacturers_general NVS
$97.11
price up icon 0.35%
drug_manufacturers_general MRK
$98.05
price down icon 1.48%
大文字化:     |  ボリューム (24 時間):